Dermatology and aesthetics vertical
Dermatology practice acquisitions: a PE guide.
Dermatology practice acquisitions have attracted more private equity capital than almost any other medical specialty, and the competition for quality practices has intensified as a result. Derm and aesthetics offer what few healthcare sub-sectors can: predictable procedure volume, favourable reimbursement, and scalable unit economics under a shared-services model. The structural logic for consolidation is clear, which is why buyer count in this vertical has climbed every year since 2018.
The problem that follows from that buyer density is equally clear: practices worth acquiring rarely hit the market at fair prices. By the time a broker sends a confidential information memorandum, five other PE funds have already seen it. The way to win is to reach the practice owner before the broker does. This guide explains how healthcare-focused PE firms and investment banks build systematic sourcing programmes for dermatology practice acquisitions, what makes a practice genuinely attractive, and where most roll-up strategies go wrong.
Why are PE firms targeting dermatology practices at this scale?
Dermatology attracts PE capital because the economics of a well-run independent practice are unusually predictable. Revenue is procedural and recurring, working capital requirements are low, and the consolidation opportunity is large: thousands of independent solo and small-group practices operate below the threshold where an investment bank would approach them, yet well above the threshold where they generate meaningful EBITDA. That gap is the sweet spot for buy-and-build strategies.
Cherry Bekaert's 2025 private equity report notes that add-on acquisitions represent roughly three-quarters of all PE buyout volume. Dermatology is a canonical example of why: once a platform is established, the market for adjacent add-ons is dense, geographically concentrated, and operationally compatible. Shared billing, group purchasing, and centralised clinical support all accrue to scale.
Physician demographics amplify the opportunity. McKinsey estimates that up to $5 trillion in US business value will change hands by 2035, and CNBC reports that roughly half of all small-business owners are 55 or older with no succession plan in place. In dermatology, that demographic skew is visible: many independent practice founders are physicians in their mid-to-late 50s who have built something valuable but have not yet made a concrete exit decision.
What makes a dermatology practice an attractive acquisition target?
The best targets share a consistent profile across geography and sub-specialty. They tend to cluster around four characteristics:
- Revenue and EBITDA scale. A practice generating $1.5M to $8M in annual revenue is large enough to justify acquisition cost and diligence, but small enough that the physician has not yet engaged an investment bank. Practices in this range are systematically under-served by the intermediary market.
- Payor mix. A combination of insurance-reimbursed medical dermatology and cash-pay aesthetics (injectables, laser, cosmetic procedures) improves margin and reduces reimbursement concentration risk. Pure aesthetics practices trade at different multiples and carry different operating risk.
- Owner age and succession readiness. Physicians aged 52 to 67 who have not structured a transition are the most receptive to acquisition conversations. Earlier-career physicians are rarely sellers; later-career physicians who have already decided to sell will likely reach a broker first.
- Geographic fit. Adjacency to an existing platform site, typically within a two-hour drive, compresses integration cost and supports patient continuity. Practices outside the platform's current geography require a separate operational thesis.
How do you source dermatology practices before they reach a broker?
Direct outreach to practice owners at scale is the only reliable method for accessing off-market inventory. Brokers and healthcare business intermediaries list practices that owners have already decided to sell. By the time a listing appears, the price has been anchored by the broker's pitch deck and the competition has multiplied. Off-market sourcing means identifying the physician who is thinking about an exit but has not yet acted, and starting a conversation before a broker does.
This matters most in dermatology because the most valuable practices rarely need a broker. A physician who spent 25 years building a respected practice is not racing to list it on a marketplace. They respond to personal, relevant outreach from a buyer who understands their business and their market, not to mass acquisition solicitations.
For context: a healthcare investment bank that DealSource Systems ran direct origination for reached 14 owner conversations in the first three weeks and 133 within 90 days at /results. None of those conversations came through a broker introduction. That throughput comes from systematic, targeted outreach, not from waiting for the phone to ring.
What does a structured sourcing process for derm acquisitions look like?
A structured derm sourcing process moves through five sequential steps, from thesis definition to qualified owner conversations, with each step dependent on the quality of the one before it.
The Five-Step Derm Sourcing Programme
- 1. Define the acquisition thesis precisely. Specify target states and metros, revenue range, payor mix thresholds, and aesthetic versus medical derm split. A thesis that is too broad produces noise; one that is too narrow exhausts its list quickly. Clarity at this stage determines the quality of everything downstream.
- 2. Map the target universe. Use NPI (National Provider Identifier) data, state medical board registries, and commercial provider databases to identify every independent dermatology practice in your target geographies. For most regional roll-up strategies, this yields 400 to 2,000 practices.
- 3. Score and segment by acquisition fit. Enrich each practice record with estimated revenue (derivable from Medicare billing data, square footage, and location), physician age, solo versus group structure, and distance from the existing platform footprint. Score against the thesis criteria and segment into high, medium, and low priority tiers.
- 4. Run a sequenced multi-touch outreach campaign. Contact the highest-priority tier first with personalised outreach that references the specific market the physician serves and the platform context you are offering. Based on Danish Lead Co. / DealSource Systems data across more than 400 origination campaigns, follow-up messages account for more than half of all qualified positive replies; a single-touch campaign leaves a substantial portion of interested owners uncontacted.
- 5. Qualify and advance. A positive reply from a practice owner is not a committed seller. The goal of the first conversation is to understand the physician's timeline, personal priorities, and concerns, not to pitch a valuation. Practices that are 12 to 18 months from readiness are worth a relationship investment now.
How should outreach to derm practice owners be personalised?
Effective outreach references the physician's specific market, sub-specialty mix, and the operational context of what a partnership would mean for their practice and patients. Generic acquisition solicitations are immediately discarded. Dermatologists receive mass enquiries from roll-up buyers regularly, and a message that reads like a form letter addressed to "practice owner" signals exactly that. What gets a response is a message that demonstrates knowledge of the physician's specific market, the sub-specialty mix they have built, and the operational context of what a partnership would mean for them.
Comparing approaches to reaching practice owners reveals a consistent pattern: targeted, market-aware outreach directed to the right level of the organisation (the physician-owner directly, not the front desk) outperforms broad blasts by a substantial margin. See our outreach to business owners guide for the framework, and our healthcare deal origination post for the healthcare-specific context.
What are the key risks in dermatology roll-up strategies?
The main risks in dermatology roll-up strategies cluster around physician retention, payor contracting complexity, integration pace, and aesthetics margin assumptions. Understanding each before sourcing a practice is as important as the sourcing itself:
- Physician retention and earnouts. The practice's revenue is inseparable from the physician's relationships with patients and referral sources. Earnout structures that create misaligned incentives, or that push physicians out before patient relationships transfer, destroy value.
- Payor contracting complexity. Acquiring practices across multiple states requires renegotiating payor contracts individually. This process can take six to twelve months per contract and compresses margins in the interim.
- Integration pace outrunning capacity. Acquiring practices faster than the billing, credentialing, and operational teams can absorb them creates backlogs, billing errors, and physician frustration that accelerates attrition.
- Aesthetics margin assumptions. Platforms that push aggressively into aesthetics post-acquisition sometimes find that nurse practitioner and aesthetician-delivered services do not replace physician-generated revenue at the margin levels modelled.
For the broader add-on acquisition sourcing playbook that applies across healthcare verticals, and the behavioral health acquisitions guide for a comparable specialty consolidation context, see the linked posts.
Conclusion
Dermatology practice acquisitions are not going to get easier to win as more platforms enter the space. The sourcing edge belongs to buyers who reach physicians before a broker frames the conversation, who personalise outreach well enough to earn a response, and who build a repeatable origination system rather than relying on inbound referrals. The five-step process above is a foundation. The specific parameters depend on your platform geography and acquisition thesis.
For the sourcing infrastructure that powers this kind of programme, see how it works and our solutions. To see what direct origination produces in a healthcare context, see results.
Key Terms Glossary
Frequently asked questions
What EBITDA multiple do dermatology practices typically sell for?
Independent dermatology practices in the lower middle market typically transact at 4x to 7x EBITDA before any platform premium. Practices integrated into an established roll-up platform may be valued higher at exit as part of the combined entity. Aesthetics-heavy practices sometimes command a modest premium for their cash-pay margin, while single-physician practices at small revenue scale trade at the lower end of the range.
How long does a dermatology acquisition typically take from first contact to close?
From the first owner conversation to signed purchase agreement typically takes six to twelve months for a straightforward single-physician practice. Multi-physician groups and practices with complex payor contracts take longer. The pre-contact sourcing phase, from list-building to first response, adds another four to ten weeks depending on list size and outreach volume.
What is the difference between a medical dermatology practice and an aesthetics practice for acquisition purposes?
A medical dermatology practice derives the majority of its revenue from insurance-reimbursed diagnosis and treatment of skin conditions. An aesthetics practice derives most revenue from elective, cash-pay cosmetic procedures. Most acquisition targets sit somewhere between the two. Buyers model each revenue stream separately because margin profile, growth trajectory, and operational requirements differ.
How do PE firms handle physician employment contracts post-acquisition?
Most derm roll-ups structure physician compensation as a combination of salary and production bonus, with a retention earnout tied to employment tenure post-close. The physician typically remains the primary clinical provider for a contractual period, ranging from two to five years, before the buyer has sufficient time to build patient continuity with other providers.
Can a PE fund acquire a dermatology practice without the physician staying on post-close?
Rarely, and at significantly lower valuations. The practice's patient relationships, referral network, and revenue are largely attributable to the physician's reputation and presence. Acquisitions where the physician exits immediately at close function more like real estate transactions than medical practice acquisitions, and buyers price accordingly.
What is the minimum revenue threshold for a dermatology practice acquisition to be attractive to PE?
Most PE funds with a formal buy-and-build thesis require a minimum of $750K in EBITDA, which typically corresponds to $2M or more in revenue for a well-run practice. Smaller practices are sometimes acquired at lower valuations if they are in a strategic geography or if their physician-owner is willing to remain as a long-term employee. Independent sponsors and family offices sometimes go smaller.
How do you find dermatology practices that are not listed for sale?
The most effective method is systematic direct outreach to physician-owners built from NPI data, state medical board registries, and commercial provider databases. Enriching that list with estimated revenue, physician age, and geographic fit allows you to prioritise outreach and tailor messaging. Referral networks (accountants, lawyers, and healthcare consultants who serve derm practices) are a secondary channel but rarely produce the volume needed to fill a buy-and-build pipeline.
What is the role of a healthcare M&A advisor in derm acquisitions?
A healthcare M&A advisor may represent either the seller (helping a physician-owner structure and market the practice) or the buyer (helping a PE fund identify targets and manage the transaction process). For buyers, the advisor's sourcing role is meaningful only if they have genuine off-market relationships in the specific geography and sub-specialty, rather than recycling listings that are already available to all buyers. Many PE funds build in-house origination capability or partner with a specialist origination service to avoid dependence on the intermediary market.